Adults

The usual recommended dose is 625 mg orally once daily. May be adjusted based on clinical response.

Elderly

No specific dose adjustment is required for elderly patients, but careful monitoring is advised.

Renal_impairment

For mild to moderate renal impairment, no dose adjustment is typically needed. For severe renal impairment (CrCl < 25 mL/min), consider reducing the dose to 312.5 mg once daily or increasing the dosing interval.

Onset

Clinical effects noticeable within 2-4 weeks of regular use, peak effect after 8-12 weeks.

Excretion

Primarily excreted renally (approximately 60%) as metabolites, with a smaller portion eliminated in feces (approximately 30%).

Half life

Approximately 8-12 hours, with active metabolites contributing to longer therapeutic effect.

Absorption

Rapidly absorbed from the gastrointestinal tract; peak plasma concentrations achieved within 1-2 hours. High oral bioavailability.

Metabolism

Extensively metabolized in the liver, primarily via CYP3A4 and CYP2C19 enzymes, to several active and inactive metabolites.

CYP2C19 Inhibitors (e.g., Omeprazole)

May increase plasma concentrations of Vasodilaxin Hydrochloride. Consider dose reduction.

CYP3A4 Inhibitors (e.g., Ketoconazole, Erythromycin, Grapefruit Juice)

May increase plasma concentrations of Vasodilaxin Hydrochloride, potentially increasing side effects. Dose adjustment may be necessary.

Anticoagulants (e.g., Warfarin) and Antiplatelets (e.g., Aspirin, Clopidogrel)

Concomitant use may increase the risk of bleeding. Monitor closely for signs of hemorrhage.